A wholly owned subsidiary of New Delhi, India-based Ranbaxy Laboratories Limited (BOM: 500359), Ohm Laboratories, Inc. (Ohm), has received USFDA approval for the manufacture and marketing of market Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC).
Indicated for controlling symptoms of diarrhea plus bloating, pressure, and cramps, commonly referred to as gas, Loperamide Hydrochloride and Simethicone Tablets (OTC), has achieved a total sales of $25.3 million (IRI - MAT: June 2006) in the OTC market.
Read more from Ranbaxy press release. 
The USFDA’s Office of Generic Drugs has determined Ranbaxy's Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC) to be the bioequivalent of Imodium® Advanced Caplets, 2 mg/125 mg (OTC) of McNeil Consumer and Specialty Pharmaceuticals, a Division of McNeil PPC, Inc. (McNeil).
Comment Preview